Wanbury Limited has successfully completed a three-day current Good Manufacturing Practices (cGMP) inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility in Tanuku, Andhra Pradesh, conducted by the Ministry of Food and Drug Safety (MFDS), Republic of Korea, with zero observations. The inspection was carried out by two senior inspectors from South Korea’s MFDS, a prominent pharmaceutical regulatory authority. The assessment covered the facility’s manufacturing operations, quality management systems and compliance with applicable international cGMP requirements.
The successful outcome marks another important milestone in Wanbury’s efforts to maintain high standards of pharmaceutical manufacturing and regulatory compliance. It follows the company’s successful completion of an MFDS cGMP inspection at its Patalganga manufacturing facility in April 2026, which was also concluded with zero observations.
The consecutive inspection outcomes demonstrate the company’s consistent focus on maintaining robust quality systems and meeting the regulatory expectations of international pharmaceutical markets. Successfully clearing inspections at two manufacturing locations reinforces Wanbury’s commitment to manufacturing excellence and adherence to globally accepted quality standards.
The Tanuku facility plays an important role in the company’s API manufacturing operations. The successful inspection further reflects its focus on maintaining established manufacturing practices, strengthening quality assurance processes and ensuring compliance across its production facilities.
Wanbury continues to invest attention in improving its operational and quality systems to keep pace with changing international regulatory requirements. The company remains committed to maintaining manufacturing standards that meet global cGMP expectations while supporting the requirements of customers and regulated pharmaceutical markets.
The latest achievement strengthens Wanbury’s regulatory track record and underscores its emphasis on quality, consistency and operational discipline across its manufacturing network. With successful MFDS inspections at both Tanuku and Patalganga, Wanbury continues to reinforce its position as a pharmaceutical manufacturer focused on international quality standards and regulatory compliance.
Wanbury Limited is an Indian pharmaceutical company established in 1988. It develops and manufactures active pharmaceutical ingredients and branded formulations for domestic and international markets. Its API portfolio covers multiple therapeutic areas, and its products are exported to more than 50 countries. The company has manufacturing facilities at Tanuku in Andhra Pradesh and Patalganga in Maharashtra.